Bionime Corporation (TPE:4737)
Taiwan · Delayed Price · Currency is TWD 57.10
-2.80 (-4.67%)
May 29, 2026, 1:30 PM CST
Bionime Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,762 | 1,839 | 1,934 | 1,756 | 2,211 | 1,850 | |
Revenue Growth (YoY) | -9.47% | -4.92% | 10.15% | -20.58% | 19.50% | 10.87% |
Cost of Revenue | 1,193 | 1,211 | 1,165 | 1,040 | 1,206 | 1,067 |
Gross Profit | 569.9 | 627.81 | 768.38 | 715.65 | 1,004 | 783.13 |
Selling, General & Admin | 468.47 | 476.3 | 575.11 | 523.17 | 641.15 | 540.54 |
Research & Development | 374.14 | 354.76 | 322.33 | 242.34 | 201.98 | 187.86 |
Operating Expenses | 847.35 | 825.17 | 923.57 | 728.99 | 872.71 | 707.84 |
Operating Income | -277.44 | -197.36 | -155.19 | -13.34 | 131.42 | 75.29 |
Interest Expense | -63.86 | -64.9 | -62.19 | -48.23 | -30.65 | -19.05 |
Interest & Investment Income | 6.22 | 6.25 | 5.05 | 4.32 | 0.94 | 0.71 |
Currency Exchange Gain (Loss) | 6.99 | 6.99 | 7.41 | 5.24 | -14.96 | 0.94 |
Other Non Operating Income (Expenses) | 5.53 | 12.13 | 23.27 | 20.15 | 3.92 | 16.7 |
EBT Excluding Unusual Items | -322.56 | -236.89 | -181.66 | -31.86 | 90.67 | 74.6 |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.01 | - |
Gain (Loss) on Sale of Assets | -3.07 | -3.07 | -0.08 | -0.01 | -4.17 | -0 |
Asset Writedown | -9.45 | -9.45 | -3.98 | - | - | - |
Other Unusual Items | - | - | - | - | - | -0.01 |
Pretax Income | -335.08 | -249.41 | -185.71 | -31.88 | 86.48 | 74.59 |
Income Tax Expense | -89.18 | -70.09 | -59.71 | -38.41 | -5.34 | -14.74 |
Earnings From Continuing Operations | -245.9 | -179.32 | -126 | 6.53 | 91.82 | 89.33 |
Minority Interest in Earnings | -1.74 | -0.96 | -1.22 | -0.32 | -0.8 | -1.91 |
Net Income | -247.64 | -180.28 | -127.22 | 6.21 | 91.03 | 87.41 |
Net Income to Common | -247.64 | -180.28 | -127.22 | 6.21 | 91.03 | 87.41 |
Net Income Growth | - | - | - | -93.18% | 4.13% | 40.01% |
Shares Outstanding (Basic) | 69 | 67 | 67 | 67 | 67 | 66 |
Shares Outstanding (Diluted) | 69 | 67 | 67 | 67 | 68 | 67 |
Shares Change (YoY) | 3.18% | 0.18% | -0.44% | -0.28% | 0.98% | 0.75% |
EPS (Basic) | -3.59 | -2.68 | -1.90 | 0.09 | 1.37 | 1.32 |
EPS (Diluted) | -3.59 | -2.68 | -1.90 | 0.09 | 1.35 | 1.31 |
EPS Growth | - | - | - | -93.25% | 2.78% | 39.80% |
Free Cash Flow | 232.79 | 338.62 | -166.55 | -89.64 | 4.62 | 132.25 |
Free Cash Flow Per Share | 3.37 | 5.04 | -2.48 | -1.33 | 0.07 | 1.98 |
Dividend Per Share | - | - | - | 1.818 | 1.909 | 1.818 |
Dividend Growth | - | - | - | -4.76% | 5.03% | -3.06% |
Gross Margin | 32.34% | 34.15% | 39.73% | 40.77% | 45.42% | 42.33% |
Operating Margin | -15.74% | -10.73% | -8.03% | -0.76% | 5.95% | 4.07% |
Profit Margin | -14.05% | -9.80% | -6.58% | 0.35% | 4.12% | 4.72% |
Free Cash Flow Margin | 13.21% | 18.42% | -8.61% | -5.11% | 0.21% | 7.15% |
EBITDA | -122.71 | -41.96 | 0.65 | 128.13 | 267.54 | 213.85 |
EBITDA Margin | -6.96% | -2.28% | 0.03% | 7.30% | 12.10% | 11.56% |
D&A For EBITDA | 154.73 | 155.4 | 155.84 | 141.47 | 136.12 | 138.55 |
EBIT | -277.44 | -197.36 | -155.19 | -13.34 | 131.42 | 75.29 |
EBIT Margin | -15.74% | -10.73% | -8.03% | -0.76% | 5.95% | 4.07% |